person · Reporting owner

SCHIFF ANDREW N

Disclosed activity across 7 companies

Tapewire entity: 38918
SEC CIK: 0001172252

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 04, 2026	June 08, 2026
Elevation Oncology, Inc.ELEV · Entity 77243	10% owner	June 16, 2023	June 21, 2023
Monte Rosa Therapeutics, Inc.GLUE · Entity 4828	Director	June 11, 2026	June 12, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	10% owner	July 15, 2019	July 15, 2019
Zosano Pharma CorpZSAN · Entity 12518	10% owner	December 02, 2019	December 06, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,540	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 25,540 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03	Direct	42,350	Reported balance After 2026-06-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F3: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,987	Reported balance After 2026-06-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6: The shares underlying these restricted stock units vested on June 5, 2026.
Common StockSEC Table I · non-derivative	IndirectBy Aisling Capital IV LP	434,455	Reported balance Holding disclosure · report date 2026-06-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 434,455 F2: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

F5: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

F6: The shares underlying these restricted stock units vested on June 5, 2026.

Elevation Oncology, Inc.

Report date June 16, 2023 · Filed June 21, 2023

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, Aisling Capital Partners IV, LP, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2033-06-15	IndirectSee footnote	31,238	Reported balance After 2023-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-16 · Grant · Acquired 31,238 · Balance 31,238 F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.

Monte Rosa Therapeutics, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 · Expires 2036-06-11	Direct	25,800	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 25,800 · Balance 25,800 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Viracta Therapeutics, Inc.

Report date July 15, 2019 · Filed July 15, 2019

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, Aisling Capital Partners IV, LP, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,100,000	Reported balance After 2019-07-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-07-15 · Purchase · Acquired 2,500,000 · Balance 10,100,000 F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Zosano Pharma Corp

Report date December 02, 2019 · Filed December 06, 2019

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV, LP, Aisling Capital Partners IV LLC, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value of $0.0001SEC Table I · non-derivative	Direct	2,718,226	Reported balance After 2019-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-12-02 · Grant · Acquired 689,655 · Balance 2,718,226 F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Loxo Oncology, Inc.

Report date July 10, 2018 · Filed July 12, 2018

Jointly reported with AISLING CAPITAL III LP, Aisling Capital Partners III LP, Aisling Capital Partners III LLC, ELMS STEVE, Purcell Dennis J

Section 16 reporting ended · disclosed 2018-07-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,038,920	Reported balance After 2018-07-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-10 · Sale · Disposed 1,400,000 · Balance 2,038,920 F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Zeltiq Aesthetics Inc

Report date April 28, 2017 · Filed May 01, 2017

Section 16 reporting ended · disclosed 2017-05-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-04-28 · Disposition to issuer · Disposed 13,137 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F3: Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children.
Common StockSEC Table I · non-derivative	IndirectBy Aisling Capital III, L.P.	Reported balance After 2017-04-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-04-28 · Disposition to issuer · Disposed 1,597,742 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F4: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration. F5: Represents shares of Common Stock directly held by Aisling Capital III, LP ("Aisling") and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14	Direct	Reported balance After 2017-04-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-28 · Disposition to issuer · Disposed 1,589 · Balance 0 F6: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").

F2: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.

F3: Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children.

F4: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration.

F5: Represents shares of Common Stock directly held by Aisling Capital III, LP ("Aisling") and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc.

F6: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2026 Filed Jun 12, 2026 16:05 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	25,800	$0.00 Strike: $17.10	$0.00	Disclosure SEC source: 0001193125-26-269365 · ownership.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,800 Underlying: Common Stock · 25,800 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 05, 2026 Filed Jun 8, 2026 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001172252-26-000002 · form4-06082026_040612.xml · derivative · entry 5 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F6 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 8, 2026 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	11,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001172252-26-000002 · form4-06082026_040612.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2026 Filed Jun 8, 2026 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	10,987	$0.00	$0.00	Disclosure SEC source: 0001172252-26-000002 · form4-06082026_040612.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 04, 2026 Filed Jun 8, 2026 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $4.71	$0.00	Disclosure SEC source: 0001172252-26-000002 · form4-06082026_040612.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F3 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F4 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 13, 2025 Filed Jun 16, 2025 16:05 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	30,700	$0.00 Strike: $4.91	$0.00	Disclosure SEC source: 0000950170-25-086699 · ownership.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2035-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 06, 2025 Filed Jun 9, 2025 16:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016252 · form4-06092025_040612.xml · derivative · entry 5 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F6 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document
June 06, 2025 Filed Jun 9, 2025 16:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,793	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-016252 · form4-06092025_040612.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 05, 2025 Filed Jun 9, 2025 16:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016252 · form4-06092025_040612.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 05, 2025 Filed Jun 9, 2025 16:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001415889-25-016252 · form4-06092025_040612.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F3 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F4 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 12, 2024 Filed Jun 13, 2024 16:30 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	22,100	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0000950170-24-073064 · ownership.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 06, 2024 Filed Jun 10, 2024 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016193 · form4-06102024_040605.xml · derivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2024 Filed Jun 10, 2024 16:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001415889-24-016193 · form4-06102024_040605.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015360 · form4-06042024_040604.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F3 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015360 · form4-06042024_040604.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 16, 2023 Filed Jun 21, 2023 16:09 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	GrantStock Option (Right to Buy) · Derivative	31,238	$0.00 Strike: $1.47	$0.00	Disclosure SEC source: 0001415889-23-010090 · form4-06212023_080601.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 31,238 Underlying: Common Stock · 31,238 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2 · ownership.nature: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. Read SEC document
June 14, 2023 Filed Jun 15, 2023 16:28 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	20,500	$0.00 Strike: $6.59	$0.00	Disclosure SEC source: 0001209191-23-037352 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:53 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034411 · doc4.xml · derivative · entry 5 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F6 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:53 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034411 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:53 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034411 · doc4.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F5 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:53 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034411 · doc4.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F3 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
November 14, 2022 Filed Nov 14, 2022 16:51 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	1,371	$17.08	$23,416.68	Disclosure SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 434,455 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
November 11, 2022 Filed Nov 14, 2022 16:51 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	41,160	$17.06	$702,177.25	Disclosure SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 435,826 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2022 Filed Nov 14, 2022 16:51 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	11,395	$17.02	$193,995.32	Disclosure SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 476,986 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.165, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 26, 2022 Filed Oct 26, 2022 19:09 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	14,540	$17.01	$247,252.70	Disclosure SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 488,381 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 25, 2022 Filed Oct 26, 2022 19:09 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	12,018	$17.02	$204,516.32	Disclosure SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 502,921 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 24, 2022 Filed Oct 26, 2022 19:09 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	14,616	$17.01	$248,586.00	Disclosure SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 514,939 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 18, 2022 Filed Oct 19, 2022 16:49 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	32,093	$16.89	$542,021.89	Disclosure SEC source: 0001209191-22-054075 · doc4.xml · nonDerivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 529,555 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.23 to $17.1023, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 17, 2022 Filed Oct 19, 2022 16:49 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	19,944	$16.05	$320,087.24	Disclosure SEC source: 0001209191-22-054075 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 561,648 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 07, 2022 Filed Oct 11, 2022 16:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	7,324	$16.16	$118,349.25	Disclosure SEC source: 0001209191-22-053312 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 581,592 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 06, 2022 Filed Oct 6, 2022 17:58 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	37,839	$16.54	$625,743.54	Disclosure SEC source: 0001209191-22-053003 · doc4.xml · nonDerivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 588,916 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
October 04, 2022 Filed Oct 6, 2022 17:58 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	7,700	$16.01	$123,258.52	Disclosure SEC source: 0001209191-22-053003 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 626,755 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2022 Filed Jun 21, 2022 16:57 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	19,565	$15.14	$296,268.88	Disclosure SEC source: 0001209191-22-038451 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 17, 2022 Filed Jun 22, 2022 18:43 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	GrantStock Option (Right to Buy) · Derivative	15,619	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0001209191-22-038760 · doc4.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,619 Underlying: Common Stock · 15,619 shares Expires 2032-06-16 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2 · ownership.nature: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. Read SEC document
June 15, 2022 Filed Jun 16, 2022 16:31 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.66	$0.00	Disclosure SEC source: 0001209191-22-037429 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2023 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:36 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034617 · doc4.xml · derivative · entry 5 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F6 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:36 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034617 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:36 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034617 · doc4.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F5 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:36 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034617 · doc4.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F3 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:29 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	ConversionSeries B Preferred Stock · Derivative	1,936,834	$0.00	$0.00	Disclosure SEC source: 0001209191-21-044561 · doc4.xml · derivative · entry 5 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:29 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	ConversionSeries A Preferred Stock · Derivative	8,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-044561 · doc4.xml · derivative · entry 4 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,893,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:29 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	PurchaseCommon Stock	187,500	$16.00	$3,000,000.00	Disclosure SEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 3 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834,910 F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:29 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	ConversionCommon Stock	458,360	$0.00	$0.00	Disclosure SEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 2 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:29 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	ConversionCommon Stock	1,893,232	$0.00	$0.00	Disclosure SEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document
June 24, 2021 Filed Jun 28, 2021 18:18 UTC	Elevation Oncology, Inc. ELEV · Entity 77243	GrantDirector Stock Option · Derivative	31,238	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-21-043527 · doc4.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,238 Underlying: Common Stock · 31,238 shares Expires 2031-06-23 F1 · derivative.exercise_date: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. The stock option vests as of 1/36 of the total shares monthly beginning on July 24, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 23, 2021 Filed Jun 25, 2021 17:01 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	GrantStock Option (Right to Buy) · Derivative	47,132	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-21-025981 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,132 Underlying: Common Stock · 47,132 shares Expires 2031-06-22 F1 · derivative.exercise_date: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:12 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038459 · doc4.xml · derivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:12 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001209191-21-038459 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035029 · doc4.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	7,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-035029 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.